Why the study?
DM and AF increase thromboembolic risk, but DM-related vascular complications and comorbidities may also influence bleeding risk during anticoagulation therapy.
Does diabetes mellitus status increase the risk of thromboembolic and bleeding events in patients with atrial fibrillation treated with edoxaban?
Population
3299 patients with AF receiving edoxaban at baseline
Comparison
DM (insulin-treated or not) vs no DM
Design
Prospective, observational, non-interventional registry sub-analysis
Follow-up
2-year follow-up
Authors
Loading...
DM associated with higher major GI bleeding on edoxaban in AF; hypothesis-generating and should not yet change practice.
Does diabetes mellitus status increase the risk of thromboembolic and bleeding events in patients with atrial fibrillation treated with edoxaban?
In Asian patients with atrial fibrillation taking edoxaban, diabetes mellitus is associated with a significantly higher risk of major GI bleeding and worse net clinical outcomes, but not a significantly higher risk of stroke.
Chao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: